# MOTS-c legal status, FDA 503A Category & Compounding | MOTS-c peptide > MOTS-c legal status: the MOTS-c peptide is not an FDA-approved drug, is sold only as a research chemical, and is named on the FDA PCAC agenda for July 23-24, 2026 as a substance being considered for the 503A bulks list. Access is under active FDA review and may expand in 2026 — anchored to one fact: MOTS-c is named on the FDA Pharmacy Compounding Advisory Committee agenda for July 23-24, 2026. A scheduled evaluation, not a decision. ## The short version Here is the MOTS-c legal status in plain terms. MOTS-c is not an FDA-approved drug for anything, and it is not a dietary supplement; it is sold only as a research chemical for laboratory use. The forward-looking part: the FDA is actively reviewing whether certain peptides can be used in pharmacy compounding, and MOTS-c is specifically named on the agenda of an FDA advisory-committee meeting set for July 23-24, 2026. That meeting is a scheduled discussion — a step in evaluation. It is not a decision, not a reclassification, and not a change to today's status. Nothing below is medical or legal advice, and this site sells nothing. ## Current status: research peptide, not FDA-approved MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is **not an FDA-approved drug for any indication** [16]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance (an active ingredient used as a starting material, rather than a finished approved drug) may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) [16]. MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation [18]. Being under evaluation is not the same as being on the bulks list or approved for compounding. The published FDA materials that establish a numbered 503A safety category do so for other specific peptides; this digest does not assign MOTS-c a 503A Category, because FDA's audited record places it in evaluation, not in a numbered category [16][18]. ## Under active review: the July 23-24, 2026 PCAC agenda The momentum is real, and it is anchored to a single verifiable fact: MOTS-c is **individually named on the published agenda** of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for **July 23-24, 2026**, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. FDA's calendar lists it for evaluation in both free-base and acetate forms, and the same agenda lists BPC-157, TB-500, and KPV [18]. That is a scheduled evaluation and discussion only. A PCAC discussion is advisory; it is **not** a listing decision, **not** a reclassification, and **not** a change in MOTS-c's current status [18]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being discussed by the committee is a step in evaluation, not the outcome [16]. The outcome of the July 2026 meeting is unknown and is not assumed here. This page states present-tense facts and cites FDA; it does not assert any future FDA action as already done, dated, or certain. ## How legally compounded peptide access works Compounding in the U.S. runs through two sections of the law. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [16]. The lawful access pathway is: a patient is evaluated by an appropriately licensed prescriber (in person or via a compliant telehealth encounter, which can serve as the front-end channel for the consultation); if appropriate and lawful, the prescriber issues a valid, patient-specific prescription; and the preparation is dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [16]. Telehealth is a route to a licensed-prescriber consultation, not a separate legal status — it does not expand which substances may be compounded [16]. One ingredient-eligibility caveat governs all of this: the compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and a substance that FDA has flagged for significant safety risks (a Category 2 substance) is not eligible for routine 503A compounding while that status stands [16]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. ## Is MOTS-c a Supplement? Research-Only Status ### Is MOTS-c a Supplement? Research-Only Status MOTS-c is not a dietary supplement and is not an over-the-counter product. It has no FDA-approved indication, formulation, or dosing, and it is sold only as a research chemical for laboratory use [16]. Product purity, identity, and sterility vary by supplier and are not regulated as pharmaceuticals. This site is an editorial research digest: it describes the regulatory landscape and the published literature, and it does not sell, recommend, or supply MOTS-c or name any vendor. ### Is MOTS-c legal? MOTS-c is not an FDA-approved drug and is not a dietary supplement; it is sold only as a research chemical for laboratory use [16]. It is named on the FDA PCAC agenda for July 23-24, 2026 as a substance being considered for the 503A bulks list — a scheduled evaluation, not a change in current status [18]. ### What is the FDA 503A status of MOTS-c? MOTS-c is not on the FDA 503A bulks list and is not an FDA-approved drug; it is scheduled for PCAC evaluation at the July 23-24, 2026 meeting [18]. A bulk substance may be used in 503A compounding only if it has a USP/NF monograph, is a component of an approved drug, or is on the bulks list — none of which currently applies to MOTS-c [16]. ### Can you get MOTS-c from a compounding pharmacy? Legally compounded medicines require a valid, patient-specific prescription from a licensed prescriber, filled by a 503A pharmacy or 503B outsourcing facility, and the ingredient must be eligible under the bulk-substance rules [16]. MOTS-c is not on the 503A bulks list and is under FDA evaluation, so it is not eligible for routine 503A compounding while that status stands [16][18]. --- A depth-gauged reading of the MOTS-c mitochondrial-peptide record — the human signal logged near the surface, the preclinical findings in the mid-water, and the honest gaps left visible in the abyss, with no clinic behind the gauge and nothing here stocked, priced, or sold.